Status:
COMPLETED
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
Novartis
Conditions:
Non-small Cell Lung Cancer
Bone Metastases
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small ce...
Eligibility Criteria
Inclusion
- Age \>18, either sex
- Histologically confirmed non-small cell cancer
- One bone metastasis at least confirmed by image(X ray,CT or others)
- Without receiving zoledronic acid
- Life expectancy \> 6 M
- ECOG \<= 2
- Signed ICF
Exclusion
- Women who are pregnant or in lactation
- Patients with hyperostosis
- with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled
- Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy
- Severe co-morbidity of any type that may interfere with assessment of the patient for the study -
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
432 Patients enrolled
Trial Details
Trial ID
NCT00765687
Start Date
August 1 2008
End Date
May 1 2012
Last Update
December 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SunYat-senU
Guangzhou, Guangdong, China